Navigation Links
ProLindac in Medical News

Access Pharmaceuticals Announces New MuGard Commercial Strategy in North America

...ded, and that involve risks and uncertainties. These statements include those relating to: clinical trial plans and timelines and clinical results for prolindac and product candidates acquired in the MacroChem transaction, our ability to execute licensing agreements in the future, Access' plans to continue and...

Access Pharmaceuticals Announces Commercial Launch of MuGard(TM) in Norway by SpePharm

...ded, and that involve risks and uncertainties. These statements include those relating to: clinical trial plans and timelines and clinical results for prolindac and product candidates acquired in the MacroChem transaction, our ability to execute licensing agreements in the future, Access' plans to continue and...

UPDATE: Access Pharmaceuticals to Present at Jesup & Lamont 2009 Growth Stock Conference

...ded, and that involve risks and uncertainties. These statements include those relating to: clinical trial plans and timelines and clinical results for prolindac and product candidates acquired in the MacroChem transaction, our ability to execute licensing agreements in the future, Access' plans to continue and...

Access Pharmaceuticals to Present at Jesup & Lamont 2009 Growth Stock Conference

...ded, and that involve risks and uncertainties. These statements include those relating to: clinical trial plans and timelines and clinical results for prolindac and product candidates acquired in the MacroChem transaction, our ability to execute licensing agreements in the future, Access' plans to continue and...

Access Pharmaceuticals to Present at Jessup & Lamont 2009 Growth Stock Conference

...ded, and that involve risks and uncertainties. These statements include those relating to: clinical trial plans and timelines and clinical results for prolindac and product candidates acquired in the MacroChem transaction, our ability to execute licensing agreements in the future, Access' plans to continue and...

Access Pharmaceuticals Announces Commercial Launch of MuGard(TM) in Greece by SpePharm

...ded, and that involve risks and uncertainties. These statements include those relating to: clinical trial plans and timelines and clinical results for prolindac and product candidates acquired in the MacroChem transaction, our ability to execute licensing agreements in the future, Access' plans to continue and...

Access Pharmaceuticals Provides Update on ProLindac(TM) Phase 2 Ovarian Cancer Trial and Clinical Development Plan

... prolindac Showing High DACH Platinum Activity; Drug Well Tol...s in the Company's clinical development plan for prolindac , a novel DACH platinum drug that has shown t...lts from its Phase 2 monotherapy clinical study of prolindac (TM) in late-stage, heavily pretreated ovarian ...

Access Pharmaceuticals Provides Update on Global Launch of MuGard(TM)

...ded, and that involve risks and uncertainties. These statements include those relating to: clinical trial plans and timelines and clinical results for prolindac and other product candidates, our ability to execute licensing agreements in the future, Access' plans to continue and initiate clinical trials, the v...

Access Pharmaceuticals Closes Acquisition of MacroChem Corp.

...ded, and that involve risks and uncertainties. These statements include those relating to: clinical trial plans and timelines and clinical results for prolindac and product candidates acquired in the MacroChem transaction, our ability to execute licensing agreements in the future, Access' plans to continue and...

Access Pharmaceuticals Presents ProLindac(TM) Data at the AACR-NCI-EORTC Symposium 2008

... - prolindac Is Safe And Active in Recurrent Ovarian Cancer; Un... France where the level of anti-cancer activity of prolindac in a heavily-pretreated patient population compare...s in France, demonstrate the potential benefits of prolindac over current platinum therapies: one highlights th...
ProLindac in Medical Technology

Access Pharmaceuticals Provides Update on ProLindac Clinical Development Program

DALLAS, Aug. 3 /PRNewswire-FirstCall/ -- ACCESS PHARMACEUTICALS, INC. (OTC Bulletin Board: ACCP), provided an update today on its clinical development strategy for ProLindac , a novel DACH platinum drug that has shown to be active in many solid tumors in human cli...

Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac

Company Announces Clinical Trial Plans for 4Q07/1Q08 DALLAS, Aug. 20 /PRNewswire-FirstCall/ -- Access Pharmaceuticals, Inc. (OTC Bulletin Board: ACCP) provided today an update on the clinical development plan of ProLindac, its novel DACH platinum polymer prodrug, and announced plans ...

Thiarabine Demonstrates a Reduction of Both Inflammatory and Erosive Disease Parameters in Rheumatoid Arthritis

...ded, and that involve risks and uncertainties. These statements include those relating to: clinical trial plans and timelines and clinical results for prolindac and product candidates acquired in the MacroChem transaction, our ability to execute licensing agreements in the future, Access' plans to continue and...

Access Pharmaceuticals Announces Publication of Thiarabine Combination Data

...ded, and that involve risks and uncertainties. These statements include those relating to: clinical trial plans and timelines and clinical results for prolindac and product candidates acquired in the MacroChem transaction, our ability to execute licensing agreements in the future, Access' plans to continue and...

Access Pharmaceuticals Announces Positive ProLindac(TM) Phase 2 Ovarian Cancer Clinical Trial Results

... high dose groups achieved disease stabilization. prolindac was well tolerated overall. DALLAS, March 5 /...ffect of the approved DACH platinum, Eloxatin, and prolindac was well tolerated overall. The maximum tolerated dose of prolindac was established as well as the recommended dose le...

Access Licenses ProLindac(TM) and MuGard(TM) to JCOM Ltd, an Affiliate of DONG-A Pharmaceuticals in Korea

...lop and commercialize Access' proprietary products prolindac and MuGard for the Republic of Korea. prolindac is Access' novel DACH platinum prodrug currently i...h a double digit royalty upon commercialization of prolindac and MuGard. In addition, in co-operation with Acce...

Access Pharmaceuticals Presents Favorable Ovarian Cancer Data and Clinical Update on ProLindac(TM) Development at Prestigious International Symposium

... prolindac Demonstrates Sustained and Significant Reductions ...Efficacy Results from an Ongoing Clinical Study of prolindac in Recurrent Ovarian Cancer." prolindac is Access' novel DACH platinum-polymer prodrug, wh...

Access Pharmaceuticals Announces Two Poster Presentations Reporting Significant Preclinical Data on ProLindac(TM) at the AACR-NCI-EORTC 'Molecular Targets and Cancer Therapeutics' Conference

...potential benefits for cancer therapy of combining prolindac with other anticancer agents. "These studies, whi...s year, provide further support to our belief that prolindac has the potential to become an important tool in t...he second poster demonstrates that combinations of prolindac with certain other anticancer compounds produces c...

Access Pharmaceuticals to Present Data on ProLindac(TM) at the AACR-NCI-EORTC 'Molecular Targets and Cancer Therapeutics' Conference

...n San Francisco, CA. An update on Access' ongoing prolindac Phase 2 clinical study will be presented during Po...uesday, October 23, 2007 from 12:30 p.m. PDT. New prolindac preclinical data will appear in two posters presen...toxics, in human colon and ovarian cancer cells." prolindac is a novel DACH platinum prodrug which has been sh...

Access Pharmaceuticals Announces Poster Presentations on ProLindac at the American Association for Cancer Research 2007 Annual Meeting

...titutes in France. "We are delighted to have two prolindac poster presentations at one of the most prestigiou...re platinum could be administered to patients with prolindac than oxaliplatin before the onset of toxicity. We are currently studying prolindac in a Phase 2 monotherapy trial, treating patients ...
ProLindac in Biological Technology

MuGard Data From UK Study Shows Prevention of Oral Mucositis in Head and Neck Cancer Patients

...nd that involve risks and uncertainties. These statements include those relating to: clinical trial plans and timelines and clinical results for prolindac and product candidates acquired in the MacroChem transaction, our ability to execute licensing agreements in the future, Access' plans to continue a...

Access Pharmaceuticals Announces Granting of Two US Patents for MuGard(TM)

...ded, and that involve risks and uncertainties. These statements include those relating to: clinical trial plans and timelines and clinical results for prolindac and product candidates acquired in the MacroChem transaction, our ability to execute licensing agreements in the future, Access' plans to continue and...

Access Pharmaceuticals Announces the European Launch of MuGard(TM) by its European Partner, SpePharm

...ded, and that involve risks and uncertainties. These statements include those relating to: clinical trial plans and timelines and clinical results for prolindac and product candidates acquired in the MacroChem transaction, our ability to execute licensing agreements in the future, Access' plans to continue and...

Access Pharmaceuticals Presents New Data on ProLindac(TM) at the 2009 AACR Annual Meeting

... - Data demonstrates that prolindac should provide sustained tumor exposure to platinu...iopolymer" was presented on Monday, April 20. prolindac is Access' novel polymer-based DACH platinum prodr...ovides in vitro and ex-vivo data on the binding of prolindac to blood components, and suggests a mechanistic ra...

Access Pharmaceuticals to Present at the Rodman & Renshaw Annual Global Investment Conference

...nd can be accessed at: http://www.wsw.com/webcast/rrshq14/accp.ob . The replay can be obtained at the same link for 90 days. About ProLindac(TM): prolindac is a novel DACH platinum prodrug which has been shown to be active in a wide variety of solid tumors in both preclinical models and in human trials. A...

Access Pharmaceuticals to Present at the Noble Financial Equity Conference

...ommended that interested parties register at least 15 minutes prior to the start of the presentation to ensure timely access. About ProLindac(TM): prolindac is a novel DACH platinum prodrug which has been shown to be active in a wide variety of solid tumors in both preclinical models and in human trials. A...

Access Pharmaceuticals Signs Merger Agreement to Acquire MacroChem Corp.

...hese opportunities involve compounds that MacroChem believes show promising late-stage, pre-clinical and early clinical data. About ProLindac(TM): prolindac is a novel DACH platinum prodrug which has been shown to be active in a wide variety of solid tumors in both preclinical models and in human trials. A...

Access Licenses ProLindac(TM) to Jiangsu Aosaikang Pharmaceutical Co., LTD., a Leading Oncology Pharmaceutical Company for Manufacturing, Development and Commercialization in the Greater China Region

...he Macau Special Administrative Region and Taiwan. prolindac is Access' novel DACH platinum prodrug currently i...r obtaining the necessary regulatory approvals for prolindac and commercializing the product in the Greater Chi...an of ASK. "We are excited about the potential for prolindac in China, and we are committed to bringing excitin...

Access Pharmaceuticals to Present at the Rodman & Renshaw 5th Annual Global Healthcare Conference

....wsw.com/webcast/rrshq13/accp.ob . The replay can be obtained at the same link for up to 90 days after the live presentation. About ProLindac(TM): prolindac is a novel DACH platinum prodrug which has been shown to be active in a wide variety of solid tumors in both preclinical models and in human trials. A...

Access Pharmaceuticals Announces $2.7 Million New Equity

... Stock will be amended. Closing of the transaction is subject to the fulfillment of customary and usual closing conditions. About ProLindac(TM): prolindac is a novel DACH platinum prodrug which has been shown to be active in a wide variety of solid tumors in both preclinical models and in human trials. A...
Other Tags
(Date:11/22/2014)... 2014 (HealthDay News) -- Those air-blown hand dryers in ... paper towels, a new study suggests. British researchers ... of volunteers in order to simulate poorly washed hands. ... dryers or paper towels to dry their hands. ... amounts of germs around both types of dryers than ...
(Date:11/22/2014)... Amy Norton HealthDay Reporter ... live in nursing homes may commonly deal with aggressive or ... The study of 10 centers in New York state found ... percent of residents were involved in some type of incident ... verbal clash, with someone yelling or cursing at another resident. ...
(Date:11/21/2014)... Lauderdale, FL (PRWEB) November 21, 2014 Body ... services announced that it accepts Spafinder massage gift cards ... and in room hotel massage in all service areas including ... you don't have to go to the spa at all ... Owner and Founder of Body Well. "We may not be ...
(Date:11/21/2014)... THURSDAY, Nov. 20, 2014 (HealthDay News) -- Certain genes ... in up to a fifth of people with type ... has long been pondered by doctors working with diabetic ... have been under the impression that exercise helps decrease ... Dr. Maria Pena, director of the Center for Weight ...
(Date:11/21/2014)... 2014 MLF Biotech, Inc. has developed ... Liv-Pro® Probiotics for Pets helps maintain digestive health and ... pet's intestinal flora after it experiences a period of ... Probiotics for Pets is a proprietary blend of pure ... live active bacteria strains that are safe and effective ...
Breaking Medicine News(10 mins):Health News:Restroom Hand Dryers Spread More Germs Than Paper Towels, Study Finds 2Health News:Senior-to-Senior Aggression Common in U.S. Nursing Homes 2Health News:Senior-to-Senior Aggression Common in U.S. Nursing Homes 3Health News:Body Well Mobile Massage Announces Acceptance of Spafinder Gift Cards for In Home Massage, Hotel Massage for Travelers 2Health News:Exercise Might Not Help Some Type 2 Diabetics Control Their Blood Sugar 2Health News:Exercise Might Not Help Some Type 2 Diabetics Control Their Blood Sugar 3Health News:MLF Biotech Introduces Liv-Pro Probiotics for Pets 2
(Date:11/7/2014)... SPRINGS, Florida , November 6, 2014 ... secure authentication for better mobile security revolutionizing online transactions.  Companies ... ), Alibaba Holdings Ltd. (NYSE: BABA ), Google ... MSFT ), eBay Inc. (NASDAQ: EBAY ) ... NXTD and NXTDW), a biometric authentication company ...
(Date:11/6/2014)... deaths occur because of metastasis, yet progress in ... slow. , "It,s been particularly challenging to design ... research fellow in systems biology at Harvard Medical ... until after they,ve already metastasized." , Gujral and ... should help researchers better understand how metastasis begins. ...
(Date:11/6/2014)... Baltimore, MD, November 6, 2014 - Insilico Medicine, ... in aging and age related diseases announced a ... medicine of cancer, Champions Oncology, Inc (OTC: CSBR). ... genomics for personalized medicine, but Champions Oncology,s TumorGraft ... can validate the chemotherapy regimen experimentally generating vast ...
Breaking Biology News(10 mins):Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 2Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 3Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 4Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 5Universal Authentication Methods Provide More Secure Operations for Biometrics Devices - Company Joins FIDO Alliance for Consumer Protection 6Migration negation 2Migration negation 3Insilico Medicine, Inc announces research collaboration with Champions Oncology, Inc 2
Other Contents